The FDA has granted Breakthrough Therapy Designation for MDMA-assisted psychotherapy for PTSD. This means the FDA agrees that this treatment may have a meaningful advantage and greater compliance over available medications for PTSD.
The first FDA-regulated Phase 3 trial of MDMA-assisted psychotherapy for PTSD is underway, and MAPS is preparing to expand to Phase 3 trials in seven European countries in 2020. We are currently seeking funding in support of MAPS’ mission to make psychedelic therapy a legal treatment around the world.
maps.org
The first FDA-regulated Phase 3 trial of MDMA-assisted psychotherapy for PTSD is underway, and MAPS is preparing to expand to Phase 3 trials in seven European countries in 2020. We are currently seeking funding in support of MAPS’ mission to make psychedelic therapy a legal treatment around the world.
maps.org